MX9302160A - Composiciones farmaceuticas del interferon de leu cocito humano concordante. - Google Patents

Composiciones farmaceuticas del interferon de leu cocito humano concordante.

Info

Publication number
MX9302160A
MX9302160A MX9302160A MX9302160A MX9302160A MX 9302160 A MX9302160 A MX 9302160A MX 9302160 A MX9302160 A MX 9302160A MX 9302160 A MX9302160 A MX 9302160A MX 9302160 A MX9302160 A MX 9302160A
Authority
MX
Mexico
Prior art keywords
interferon
pharmaceutical compositions
cocit
concording
leu
Prior art date
Application number
MX9302160A
Other languages
English (en)
Inventor
Lawrence M Blatt
Milton W Taylor
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25352556&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX9302160(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX9302160A publication Critical patent/MX9302160A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se describen métodos para el tratamiento de enfermedades de proliferación celular, infecciones virales, y otras condiciones, sin provocar efectos colaterales significativos que normalmente se asocian con la terapia mediante interferón, los métodos involucran administrar a un paciente en necesidad del mismo una cantidad terapéuticamente efectiva de interferón de leucocito humano consensual o concordante. También se describen composiciones farmacéuticas del interferón de leucocito humano concordante.
MX9302160A 1992-04-15 1993-04-14 Composiciones farmaceuticas del interferon de leu cocito humano concordante. MX9302160A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/868,916 US5372808A (en) 1990-10-17 1992-04-15 Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect

Publications (1)

Publication Number Publication Date
MX9302160A true MX9302160A (es) 1994-05-31

Family

ID=25352556

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9302160A MX9302160A (es) 1992-04-15 1993-04-14 Composiciones farmaceuticas del interferon de leu cocito humano concordante.

Country Status (27)

Country Link
US (1) US5372808A (es)
EP (3) EP1419782A1 (es)
JP (2) JPH07505894A (es)
KR (1) KR950701350A (es)
CN (1) CN1098103C (es)
AT (1) ATE254926T1 (es)
AU (1) AU683214B2 (es)
CA (1) CA2118121C (es)
CZ (1) CZ247194A3 (es)
DE (1) DE69333321T3 (es)
DK (1) DK0911033T4 (es)
ES (1) ES2210864T5 (es)
HK (1) HK1018595A1 (es)
HU (1) HU227310B1 (es)
IL (1) IL105366A (es)
MX (1) MX9302160A (es)
NO (1) NO318643B1 (es)
NZ (1) NZ252871A (es)
PT (1) PT911033E (es)
RO (1) RO115700B1 (es)
RU (1) RU2128056C1 (es)
SG (1) SG52443A1 (es)
SK (1) SK284712B6 (es)
TW (1) TW265265B (es)
UA (1) UA44223C2 (es)
WO (1) WO1993021229A1 (es)
ZA (1) ZA932641B (es)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
JP2989002B2 (ja) * 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US20020177688A1 (en) * 1988-12-22 2002-11-28 Kirin-Amgen, Inc., Chemically-modified G-CSF
US5906816A (en) * 1995-03-16 1999-05-25 University Of Florida Method for treatment of autoimmune diseases
US6372206B1 (en) 1989-03-02 2002-04-16 University Of Florida Orally-administered interferon-TAU compositions and methods
US5372808A (en) † 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5676942A (en) * 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
ATE179330T1 (de) * 1992-02-10 1999-05-15 Interferon Sciences Inc Verbesserte alpha-interferon-zusammensetzung und verfahren zu ihrer herstellung aus leukocyten des menschlichen peripheren blute
US6001589A (en) * 1993-06-11 1999-12-14 Pbl Biomedical Laboratories, Inc. Method of identifying proteins modified by disease states related thereto
JPH09501827A (ja) * 1993-06-11 1997-02-25 ペストカ バイオメディカル ラボラトリーズ インコーポレイテッド インターフェロンおよびインターロイキンを含む超タンパク質
WO1995015177A2 (en) * 1993-12-02 1995-06-08 President And Fellows Of Harvard College Improved efficacy of alpha-helical cytokines
AU1916295A (en) * 1994-02-08 1995-08-29 Amgen, Inc. Oral delivery of chemically modified proteins
US20030053982A1 (en) * 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
IL116730A0 (en) * 1995-01-13 1996-05-14 Amgen Inc Chemically modified interferon
US6214535B1 (en) * 1995-08-30 2001-04-10 Toray Industries, Inc. Method for testing cardiac myocarditis or cardiomyopathy
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
DE69632062T2 (de) 1995-11-02 2004-11-18 Schering Corp. Kontinuierliche, niedrigdosierte zytokine-infusionstherapie
US5739313A (en) * 1995-11-13 1998-04-14 Regents Of The University Of Minnesota Radionuclide labeling of vitamin B12 and coenzymes thereof
US20030026779A1 (en) * 1999-10-15 2003-02-06 Liming Yu Treatment of tumors and viral infections with a hybrid conjugate of interferon and an immunoglobulin Fc
US5980884A (en) * 1996-02-05 1999-11-09 Amgen, Inc. Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
AUPN976596A0 (en) * 1996-05-09 1996-05-30 Pharma Pacific Pty Ltd Stimulation of host defence mechanisms
US5831062A (en) * 1996-05-09 1998-11-03 Amgen Inc. Use of the human interferon consensus gene for gene therapy
CA2253971A1 (en) * 1996-05-09 1997-11-13 Pharma Pacific Pty.Ltd. Use of high dose interferon by oralmucosal contact to treat viral infections and neoplastic conditions
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
US6017876A (en) 1997-08-15 2000-01-25 Amgen Inc. Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
US6013253A (en) * 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
WO2000018427A1 (en) * 1998-09-29 2000-04-06 Fleischmann W Robert Methods of treating diseased cells
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US6451346B1 (en) * 1998-12-23 2002-09-17 Amgen Inc Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
RU2140285C1 (ru) * 1999-01-25 1999-10-27 Гапонюк Петр Яковлевич Противовирусное средство - капли в нос "гриппферон"
HU228488B1 (en) * 1999-01-29 2013-03-28 Amgen Inc Gcsf conjugates
US6806363B1 (en) 1999-04-16 2004-10-19 Mayo Foundation For Medical Education & Research Cobalamin conjugates useful as antitumor agents
US8106098B2 (en) * 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
US7591995B2 (en) * 1999-10-15 2009-09-22 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging and therapeutic agents
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EA200601591A1 (ru) 2000-05-26 2007-02-27 Айденикс (Кайман) Лимитед Применение рибонуклеозидных соединений для лечения флавивирусных и пестивирусных инфекций
US7105154B2 (en) * 2000-07-19 2006-09-12 Pepgen Corporation Method of treatment using interferon-tau
EP1334114A2 (en) 2000-10-25 2003-08-13 Mayo Foundation For Medical Education And Research Transcobalamin binding conjugates useful for treating abnormal cellular proliferation
US6878364B2 (en) * 2000-12-01 2005-04-12 Cornell Research Foundation, Inc. Animal model for flaviviridae infection
US20050079579A1 (en) * 2001-02-28 2005-04-14 Guangwen Wei Uses of spatial configuration to modulate protein function
US20060035327A1 (en) * 2001-02-28 2006-02-16 Guangwen Wei Recombinant super-compound interferon and uses thereof
CN1245215C (zh) * 2001-02-28 2006-03-15 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
US8551469B2 (en) * 2001-02-28 2013-10-08 Superlab Far East Limited Treatment of tumors and viral diseases with recombinant interferon alpha
US20030104996A1 (en) * 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
CN1561227A (zh) * 2001-09-28 2005-01-05 印特缪恩股份有限公司 在治疗失败的病人中治疗丙型肝炎病毒感染的方法
EP1435973A4 (en) * 2001-09-28 2007-05-02 Mayo Foundation SIMULTANEOUS ADMINISTRATION OF A TRANSPORT PROTEIN WITH CONJUGATED COBALAMINE FOR THE DISTRIBUTION OF MEDICINAL PRODUCTS
PL369129A1 (en) * 2001-09-28 2005-04-18 Intermune, Inc. Method for treating hepatitis c virus infection in treatment failure patients
JP2005504087A (ja) * 2001-09-28 2005-02-10 イデニクス（ケイマン）リミテツド ４’が修飾されたヌクレオシドを使用するｃ型肝炎ウイルス治療のための方法および組成物
BR0213103A (pt) * 2001-10-05 2004-09-21 Intermune Inc Método para tratamento de infecção pelo vìrus da hepatite com um perfil de liberação de interferon multifásico
WO2003049760A1 (en) * 2001-12-07 2003-06-19 Intermune, Inc. Compositions and method for treating hepatitis virus infection
JP2006501137A (ja) * 2002-01-16 2006-01-12 ペプジェン コーポレイション インターフェロン−τの経口投与
US20040063912A1 (en) * 2002-03-15 2004-04-01 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
US7456155B2 (en) 2002-06-28 2008-11-25 Idenix Pharmaceuticals, Inc. 2′-C-methyl-3′-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
TW200500373A (en) 2002-06-28 2005-01-01 Idenix Cayman Ltd 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
CN101172993A (zh) 2002-06-28 2008-05-07 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
GB0215293D0 (en) * 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
HUE033832T2 (en) 2002-11-15 2018-01-29 Idenix Pharmaceuticals Llc 2'-methyl nucleosides in combination with interferon and Flaviviridae mutation
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
MXPA05006230A (es) 2002-12-12 2005-09-20 Idenix Cayman Ltd Proceso para la produccion de nucleosidos ramificados-2'.
US20070077225A1 (en) * 2003-02-28 2007-04-05 Blatt Lawrence M Continuous delivery methods for treating hepatitis virus infection
WO2005013917A2 (en) * 2003-02-28 2005-02-17 Intermune, Inc. Combination therapy for treating alphavirus infection and liver fibrosis
SI1633766T1 (sl) 2003-05-30 2019-06-28 Gilead Pharmasset Llc Modificirani analogi fluoriranih nukleozidov
WO2005009418A2 (en) 2003-07-25 2005-02-03 Idenix (Cayman) Limited Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis c
ES2528218T3 (es) * 2003-08-28 2015-02-05 Superlab Far East Limited Usos de interferones con estructura espacial modificada
KR20060130009A (ko) 2003-08-28 2006-12-18 휴이양테크 (유에스에이), 인크. 변경된 공간 구조를 갖는 인터페론의 용도
US7585647B2 (en) * 2003-08-28 2009-09-08 Guangwen Wei Nucleic acid encoding recombinant interferon
AU2004281780B2 (en) 2003-10-14 2009-03-19 F. Hoffmann-La Roche Ltd Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication
EP1706403B9 (en) * 2003-12-22 2012-07-25 K.U.Leuven Research & Development Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment
WO2005067889A1 (en) 2003-12-30 2005-07-28 Durect Corporation Polymeric implants, preferably containing a mixture of peg and plg, for controlled release of active agents, preferably a gnrh
WO2005107742A1 (en) 2004-05-05 2005-11-17 Yale University Novel antiviral helioxanthin analogs
MXPA06013412A (es) 2004-05-19 2007-01-23 Maxygen Inc Polipeptidos de interferon-alfa y conjugados.
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
NZ554442A (en) 2004-09-14 2011-05-27 Pharmasset Inc Preparation of 2'fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
EP1679065A1 (en) * 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Controlled release compositions for interferon based on PEGT/PBT block copolymers
WO2006134497A2 (en) * 2005-03-09 2006-12-21 Guangwen Wei Uses of recombinant super-compound interferons
JP4516863B2 (ja) * 2005-03-11 2010-08-04 株式会社ケンウッド 音声合成装置、音声合成方法及びプログラム
KR20080019619A (ko) 2005-05-18 2008-03-04 맥시겐, 인크. 개량된 인터페론-알파 폴리펩티드
EP2305697A3 (en) 2005-07-25 2011-07-27 Intermune, Inc. Macrocyclic inhibitors of Hepatitis C virus replication
US8119592B2 (en) 2005-10-11 2012-02-21 Intermune, Inc. Compounds and methods for inhibiting hepatitis C viral replication
WO2007075876A2 (en) 2005-12-23 2007-07-05 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
EP2001502A1 (en) * 2006-03-31 2008-12-17 Schering Corporation Parenteral low dose type 1 interferons for bladder cancer
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
CN101525381B (zh) * 2008-03-04 2012-04-18 北京百川飞虹生物科技有限公司 一种重组复合干扰素及其表达载体的构建和表达
TW200946541A (en) * 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EA201100851A1 (ru) * 2008-12-23 2012-04-30 Фармассет, Инк. Аналоги нуклеозидов
EP2671888A1 (en) 2008-12-23 2013-12-11 Gilead Pharmasset LLC 3',5'-cyclic nucleoside phosphate analogues
MX2011006891A (es) 2008-12-23 2011-10-06 Pharmasset Inc Fosforamidatos de nucleosidos.
TWI583692B (zh) * 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
EP2440251A4 (en) * 2009-06-09 2013-01-16 Defyrus Inc INTERFERON ADMINISTRATION FOR PROPHYLAXIS AGAINST PATHOGEN INFECTION OR TREATMENT OF PATHOGEN INFECTION
WO2011014882A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. CONTINUOUS SUBCUTANEOUS ADMINISTRATION OF INTERFERON-α TO HEPATITIS C INFECTED PATIENTS
CN102101886A (zh) 2009-12-18 2011-06-22 四川辉阳生命工程股份有限公司 构象改变的重组干扰素晶体、其三维结构及应用
EP2552931B1 (en) 2010-03-31 2014-07-23 Gilead Pharmasset LLC Stereoselective synthesis of phosphorus containing actives
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
US20120123338A1 (en) 2010-06-16 2012-05-17 Medtronic, Inc. Damping systems for stabilizing medications in drug delivery devices
ES2873253T3 (es) 2010-09-28 2021-11-03 Amryt Pharmaceuticals Inc Leptinas altamente solubles
US8841275B2 (en) 2010-11-30 2014-09-23 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
BRPI1107312B1 (pt) * 2011-11-25 2021-09-08 Universidade Federal De Santa Catarina Composto de acil-hidrazona
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US8809354B2 (en) 2011-12-31 2014-08-19 Sheikh Riazuddin 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
TWI718086B (zh) 2013-01-07 2021-02-11 英屬維爾京群島商遠東超級實驗室有限公司 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物
PT3038601T (pt) 2013-08-27 2020-06-30 Gilead Pharmasset Llc Formulação combinada de dois compostos antivirais

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES506955A0 (es) † 1980-11-10 1983-02-01 Genentech Inc Un procedimiento para producir un polipeptido antiviral.
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
SE8502430L (sv) † 1985-05-15 1986-11-16 Kabivitrum Ab En cdna-molekyl som kodar for expressionen av en polypeptid av typen interferon alfa, en bakteriell eller celluler verd transformerad med en sadan molekyl och en polypeptid som uppvisar interferonaktivetet framstelld me
EP0205404B1 (en) † 1985-06-11 1992-07-15 Ciba-Geigy Ag Hybrid interferons
WO1992006707A1 (en) * 1990-10-17 1992-04-30 Amgen Inc. Methods and compositions for the treatment of cell proliferation disorders
US5372808A (en) † 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect

Also Published As

Publication number Publication date
US5372808A (en) 1994-12-13
DK0911033T4 (da) 2010-03-22
ES2210864T5 (es) 2010-03-09
HU9402979D0 (en) 1995-02-28
EP0641359A4 (en) 1995-10-04
HU227310B1 (en) 2011-03-28
HK1018595A1 (en) 1999-12-30
CN1081909A (zh) 1994-02-16
KR950701350A (ko) 1995-03-23
RU2128056C1 (ru) 1999-03-27
CA2118121A1 (en) 1993-10-28
NO943901L (no) 1994-10-14
CA2118121C (en) 2005-08-02
IL105366A (en) 1999-11-30
DE69333321T2 (de) 2004-09-16
AU683214B2 (en) 1997-11-06
EP0911033B2 (en) 2009-11-18
DE69333321D1 (de) 2004-01-08
TW265265B (es) 1995-12-11
EP1419782A1 (en) 2004-05-19
DK0911033T3 (da) 2004-03-29
SK124794A3 (en) 1995-04-12
SK284712B6 (sk) 2005-09-08
AU4293493A (en) 1993-11-18
HUT70216A (en) 1995-09-28
JP2005029561A (ja) 2005-02-03
ZA932641B (en) 1993-10-22
NO943901D0 (no) 1994-10-14
UA44223C2 (uk) 2002-02-15
EP0911033B1 (en) 2003-11-26
RO115700B1 (ro) 2000-05-30
CN1098103C (zh) 2003-01-08
NO318643B1 (no) 2005-04-25
KR100321467B1 (es) 2008-11-13
EP0911033A2 (en) 1999-04-28
EP0641359A1 (en) 1995-03-08
PT911033E (pt) 2004-04-30
WO1993021229A1 (en) 1993-10-28
IL105366A0 (en) 1993-08-18
NZ252871A (en) 1997-08-22
EP0911033A3 (en) 1999-05-19
DE69333321T3 (de) 2010-03-18
CZ247194A3 (en) 1995-04-12
ES2210864T3 (es) 2004-07-01
ATE254926T1 (de) 2003-12-15
SG52443A1 (en) 1998-09-28
JPH07505894A (ja) 1995-06-29

Similar Documents

Publication Publication Date Title
MX9302160A (es) Composiciones farmaceuticas del interferon de leu cocito humano concordante.
HUP0100092A2 (hu) Kombinációs terápia kimutatható HCV-RNS eradikációjára krónikus hepatitis-C fertőzött betegekben
MY104043A (en) Therapeutic nucleosides.
NZ226005A (en) Covalent conjugates of a human cytokine and a human immunoglobulin, processes for their manufacture and pharmaceutical compositions thereof
IL134345A0 (en) Methods for treatment of patients afflicted with multiple sclerosis using consensus interferon
IL78553A (en) Therapeutic compositions of phosphonylmethoxyalkyl adenines
MY104575A (en) Therapeutic nucleosides.
DK0713701T3 (da) 2-Brommelatonin til behandling af søvnforstyrrelser
IL93219A0 (en) Treatment of leukocyte dysfunction with gm-csf
DK347289D0 (da) Terapeutiske forbindelser
MY106603A (en) Treatment of genital warts with a combination of liquid nitrogen and recombinant dna human alpha interferon
MY119359A (en) Use of consensus interferon for reducing the side effects of interferon treatment in viral hepatitis.
EA199800770A1 (ru) Лекарственный препарат для терапевтического лечения вирусного гепатита
MY111746A (en) Therapeutic nucleosides.
GEP19991514B (en) Method for Treatment with Interferon
IT1284852B1 (it) Uso dell'interferone alfa naturale umano da cellule leucocitarie per la terapia delle epatiti virali, neoplasie e sindromi da
IT1283945B1 (it) Uso dell'interferone alfa naturale umano da cellule linfoblastoidi per la terapia delle epatiti virali, neoplasie e sindromi da